Lifeward Ltd Stock Price, News & Analysis

Lifeward (Nasdaq: LFWD) announced that a paralyzed Israeli soldier has successfully completed training and received a ReWalk Personal Exoskeleton, becoming the first Israeli war casualty to regain walking ability through this technology. The 25-year-old reserve combat soldier from the IDF Paratroopers Reserve Brigade, who suffered paralysis in both legs, underwent rehabilitation at Beilinson Hospital under Dr. Yaron Watts's supervision.

Dr. Watts described this as a 'precedent-setting historic event' and advocated for the system's recognition by the Rehabilitation Department of the Ministry of Defense, similar to smart prosthetics provided to amputees. The Israeli Rehabilitation Department is now evaluating the device's safety and effectiveness for other paralyzed Veterans following this successful case.

Lifeward (NASDAQ: LFWD) has launched the ReWalk 7 Personal Exoskeleton in the U.S. market, following FDA clearance in March 2025. This seventh-generation exoskeleton for individuals with spinal cord injury (SCI) features significant improvements including:

• Customizable walking speeds for indoor/outdoor environments
• Crutch Control system for enhanced user control
• Wrist Control smartwatch and MyReWalk mobile app integration
• Improved battery life and seamless stairs/curbs navigation
• New therapist handheld device for training

The development involved extensive testing with dozens of end users and physical therapists. This launch follows two major milestones: the 2023 addition of stairs and curbs navigation capability to ReWalk 6.0, and the 2024 establishment of a Medicare reimbursement pathway by CMS for personal exoskeletons.

Lifeward (Nasdaq: LFWD) has received FDA 510(k) clearance for its ReWalk 7, the newest generation of its personal exoskeleton device designed for individuals with spinal cord injury (SCI). This seventh-generation wearable exoskeleton enables SCI patients to stand and walk again, featuring new enhancements and upgrades.

This milestone follows significant developments including the 2023 FDA clearance of ReWalk 6.0 for stairs and curbs usage, and the 2024 Centers for Medicare & Medicaid Services (CMS) national reimbursement policy approval for qualified beneficiaries. The company, which made history in 2014 with the first FDA-cleared exoskeleton medical device for SCI patients, will commence ReWalk 7 sales in the United States once the product becomes available.

Lifeward (NASDAQ: LFWD) reported strong financial results for Q4 and full year 2024, achieving record revenue of $7.5M for Q4 and $25.7M annually, representing an 85% year-over-year growth. ReWalk Personal Exoskeleton sales surged 130% in 2024, driven by Medicare coverage.

Q4 2024 highlights include: gross margin of 24.4% (45.4% non-GAAP), operating loss of $15.2M ($3.3M non-GAAP), and net loss of $15.3M ($1.73 per share). The company ended 2024 with $6.7M in cash and no debt, supplemented by a $5.0M registered direct offering in January 2025.

For 2025 guidance, Lifeward projects revenue of $28-30M, adjusted gross margins of 47-49%, and expects to reduce non-GAAP operating loss to approximately $1M by Q4 2025 through its Sustainable Growth Plan focusing on core product lines and streamlined operations.

Lifeward (Nasdaq: LFWD) and CorLife have finalized a partnership making CorLife the exclusive distributor of the ReWalk Personal Exoskeleton for Workers' Compensation claims. The partnership, announced on March 06, 2025, aims to expand access to ReWalk's technology for individuals with spinal cord injuries (SCI) sustained at work.

The ReWalk Personal Exoskeleton is a lower-body device enabling paralyzed individuals with SCI to stand and walk, being the only personal exoskeleton capable of handling stairs and curbs in real-world environments. CorLife, a division of Numotion, will leverage its network of credentialed providers and manage all workers' compensation claims submissions for the ReWalk system.

Lifeward (Nasdaq: LFWD) and MYOLYN have expanded their exclusive partnership to enhance patient access to the MyoCycle FES Cycling Therapy System for home use. The expanded agreement allows Lifeward to manage referrals and sales of MyoCycle Home products for patients transitioning from clinical to home use.

MyoCycle is a stationary exercise bike with integrated electrical stimulation designed for individuals with muscle weakness or paralysis due to conditions like spinal cord injury, multiple sclerosis, and stroke. Previously, Lifeward managed hospital and clinic-based sales of MyoCycle Pro nationwide, as well as home use sales for VA and Workers' Compensation beneficiaries.

Under the new arrangement, MYOLYN will continue directly servicing patients already discharged from therapy. Lifeward has established the necessary case management infrastructure to support anticipated growth in the MyoCycle product line, leveraging shared resources between MyoCycle and ReWalk Exoskeleton.

Lifeward (Nasdaq: LFWD), a global leader in medical technology for people with physical limitations or disabilities, has scheduled its Q4 and fiscal year-end 2024 financial results announcement for March 7, 2025, before market open.

CEO Larry Jasinski and CFO Mike Lawless will host a conference call and live webcast at 8:30 a.m. EST to discuss the results. The webcast will be accessible through the company's website at GoLifeward.com in the Investors section and will also be archived for future viewing.

Lifeward (NASDAQ: LFWD) announced CEO Larry Jasinski's retirement after 13 years of service, with his departure planned for Q2 2025. The board has formed a special committee to search for a successor, considering both internal and external candidates.

The company provided preliminary financial results for 2024, expecting revenue of $25.7 million, within their guidance of $25-26 million. Annual GAAP operating expenses are anticipated at $33.4 million, including $5.7 million in restructuring and impairment expenses. These figures are unaudited and subject to adjustment.

Due to the CEO transition, Lifeward has postponed its February 20th virtual investor event until later in 2025. The company will announce its 2025 financial outlook during its Q4 and full-year 2024 results call, scheduled for the week of March 10, 2025.

Lifeward (NASDAQ: LFWD) has finalized a reimbursement agreement with BARMER, Germany's second-largest statutory health insurer, for ReWalk Personal Exoskeletons. The agreement covers 8.5 million beneficiaries and formalizes the reimbursement process for medically eligible individuals.

BARMER has already provided 20 ReWalk Personal Exoskeletons to beneficiaries, leading Germany in exoskeleton coverage. This agreement means approximately 45% of people with Statutory Health Insurance in Germany now have coverage policies with defined reimbursement processes for personal exoskeletons.

This development follows recent expansion in reimbursement policies, including Medicare coverage in the U.S. and state coverage in Hungary. Lifeward is positioning itself for further expansion through submissions to Medicare Advantage Programs and other U.S. commercial payers.